TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Fugl-Meyer Assessment of Upper Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of dissected lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of subjects with solicited local adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with solicited general AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with any serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in IGF-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in HAMD-17 Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of MACE (composite of all-cause death, nonfatal reinfarction, or heart failure hospitalization)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With 1 or More Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of intraoperative hemodynamic instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency and severity of tics and obsessive compulsive disorder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of allergic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DVT/TVE event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients free from symptoms after surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Clinical Impression Severity Scores on the NPI-C Subscales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of LOSS of 31 Hertz Cone Electroretinographic Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Resting Metabolic Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Circulating IGF-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Marker of Bone Formation (P1NP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Marker of Bone Resorption (CTx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction of serum levels of AGEs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in mean sitting valley value of DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Body weight after 1 year of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in number of prescribed drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Folate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Screening utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ABI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal NAVA level to unload the diaphragm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak Post-prandial Venous Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: spontaneous regression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: partial regression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: progression to CIN3 rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Resting amplitude (µV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4% Oxygen Desaturation Index (ODI, 4%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: All-cause Death
Endpoint domain: Mortality/survival
Primary endpoint: Protocol Defined MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Protocol Defined Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Remission (CR) rate after 2 cycles of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite complete remission (CRc) rate after 2 cycles of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Diagnostic Image Quality Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in IBZM striatal uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Unified Huntington's Disease Rating Scale (UHDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight gain velocity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length velocity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: head circumference velocity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adiposity (fat mass index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Surgical Skill - ICO OSCAR Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in total HIV DNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in synovial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement of good quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUC of valsartan in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of valsartan in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of valsartan in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2 of valsartan in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CL/F of valsartan in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total time needed for intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PDW and MPV parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Providers' recommendations
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Severe Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: 24-week Clinical Benefit Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Analgesic Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall Response Rate (Complete and Partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain levels in postoperative patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of intraoperative Flow Cytometry for cancer cell identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunologic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adjusted platelet measurement area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical function prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score (KOOS) Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Composite of endometritis and/or wound infection and/or other post-cesarean infections
Endpoint domain: Adverse events/effects
Primary endpoint: Safety (toxicities)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: SARS-CoV2 positive conjunctival swabs
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of RV001
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of patients with culture conversion in liquid media at 8 weeks post randomisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who discontinue treatment for any reason or die
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients with an unfavourable outcome (failure, death, recurrence, loss to follow-up)
Endpoint domain: Mortality/survival
Primary endpoint: Need for additional Prednisolone, additional antibiotics, NIV or life support machine (respirator)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pediatric rhinoconjunctivitis quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adverse events after CTL infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Product-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Severe Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Abnormal Physical Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Abnormal Laboratory Values
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in upper airway geometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with negative margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acceptability of Intervention Measure (AIM) - Goal Setting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intervention Appropriateness Measure (IAM) - Goal Setting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of Intervention Measure (FIM) - Goal Setting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of T2 Weighted Changes on Serial MRI Exam Associated With New Neurological Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of New Neurological Symptoms Without Evidence of MRI Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Experiencing Hemorrhage From the Arteriovenous Malformation (AVM)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Occlusion of AVM on Serial MRI Confirmed With Angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in radiographic apical status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma acute exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Treatment Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-limiting toxicities (DLT) of FF-10832
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of FF-10832
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of individual obstruction events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Total number of referrals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of lymphocytic chromatid breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Movement Disorders Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Mini BESTest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Functional Gait Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Action Selection Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity Level of Arbitration Regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Timing of Avoidance Behavior
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of lost to follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Radiological progression of bone fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of success using a wireless ultrasound for pediatric central venous catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Atrial fibrillation detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in maximal oxygen consumption (VO2 max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in components of the metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average Change in Heart Rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average Change in Respiratory Rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Identification of patients with peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Awake Objective Cough Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ulcer size (length, mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer size (width, mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer size (depth, mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Removal/revision or supplemental fixation of the graft material requiring reoperation at the index level
Endpoint domain: Adverse events/effects
Primary endpoint: Fusion success based on X-rays
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in neurological exam scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to First Heart Failure Hospitalisation
Endpoint domain: Mortality/survival
Primary endpoint: change in severity of depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mycology efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: side effect
Endpoint domain: Adverse events/effects
Primary endpoint: cost-effectiveness
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Number of patients needing ICU admission for severe acute respiratory failure
Endpoint domain: Mortality/survival
Primary endpoint: Adverse events in 30 minutes
Endpoint domain: Adverse events/effects
Primary endpoint: Solicited adverse events during 7 days
Endpoint domain: Adverse events/effects
Primary endpoint: Unsolicited adverse events during 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of volitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cesarean Birth Rate
Endpoint domain: Mortality/survival
Primary endpoint: Opacity of white spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cigarette Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alcohol Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Illicit Drug Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rest interval duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Tuberculosis infection or reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: Light touch sensitivity threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Thermal sensation threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Photoplethysmography of the index finger
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Annualized Count of Acute Care Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of Participants Surviving at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients that stopped antibiotics early
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dose-proportionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Role Limitation Due to Physical Health (RP)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Bodily Pain (BP)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Rate of changes in empirical antibiotic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of analgesic block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Isometric Maximum Voluntary Contraction Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk and benefit profile
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC(0-tlast) of loratadine and pseudoephedrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of loratadine and pseudoephedrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treated spontaneous and traumatic bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean change in monthly average number of migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant Failure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Foot and Ankle Ability Measure (FAAM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: time to return to work in months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Total amount of anesthetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering of blood glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptom burden (asthma symptom days)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall objective tumor response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Net Adverse Clinical Events
Endpoint domain: Adverse events/effects
Primary endpoint: Global assessment of sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Prevention of caries in enamel white spot lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Worst Itch Numeric Rating Scale (WI-NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of gross tumor volume and involved lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in functional response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degradation products of the Amyloid metabolism in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Progression from SpA to Axial Spa and to AS
Endpoint domain: Mortality/survival
Primary endpoint: Pain relief from circumcision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes